按需注射与每两个月注射一次玻璃体内阿柏西普治疗典型新生血管性年龄相关性黄斑变性的比较。
Comparison of pro re nata versus Bimonthly Injection of Intravitreal Aflibercept for Typical Neovascular Age-Related Macular Degeneration.
作者信息
Mori Ryusaburo, Tanaka Koji, Haruyama Miho, Kawamura Akiyuki, Furuya Koichi, Yuzawa Mitsuko
机构信息
Division of Ophthalmology, Department of Visual Sciences, Nihon University School of Medicine, Tokyo, Japan.
出版信息
Ophthalmologica. 2017;238(1-2):17-22. doi: 10.1159/000468950. Epub 2017 Apr 13.
PURPOSE
The aim of this study was to clarify the 1-year outcomes of pro re nata (PRN) and bimonthly intravitreal injections of aflibercept (IVA) for typical neovascular age-related macular degeneration (tAMD) after the initial 3 monthly IVA.
METHODS
We conducted a prospective, interventional study. Fifty-eight treatment-naïve patients with tAMD were randomly assigned to the PRN (30 patients) or the bimonthly (28 patients) treatment group. Both groups initially received 3 monthly IVA. Visual acuity, central macular retinal thickness (CRT), and central choroidal thickness (CCT) were evaluated at 12 months. Subanalysis was performed to identify factors associated with the best-corrected visual acuity (BCVA).
RESULTS
BCVA was significantly improved only in the bimonthly group at 12 months. CRT and CCT were significantly decreased in both groups. Subanalysis showed that the only factor associated with BCVA improvement at 12 months was the existence of pigment epithelial detachment at baseline.
CONCLUSIONS
BCVA showed significant improvement only in the bimonthly group but not in the PRN group at 12 months.
目的
本研究旨在明确在最初每月一次玻璃体内注射阿柏西普（IVA）3次后，按需（PRN）和每两个月一次玻璃体内注射阿柏西普（IVA）治疗典型新生血管性年龄相关性黄斑变性（tAMD）的1年结局。
方法
我们进行了一项前瞻性干预研究。58例初治tAMD患者被随机分配至PRN组（30例患者）或每两个月一次治疗组（28例患者）。两组最初均接受每月一次IVA共3次。在12个月时评估视力、中心黄斑视网膜厚度（CRT）和中心脉络膜厚度（CCT）。进行亚组分析以确定与最佳矫正视力（BCVA）相关的因素。
结果
仅在每两个月一次治疗组中，12个月时BCVA有显著改善。两组的CRT和CCT均显著降低。亚组分析显示，12个月时与BCVA改善相关的唯一因素是基线时存在色素上皮脱离。
结论
12个月时，仅每两个月一次治疗组的BCVA有显著改善，而PRN组未改善。
Zotero 插件